Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adenovir Pharma AB

Anti-infectives for ophthalmic indications

This article was originally published in Start Up

Executive Summary

Epidemic keratoconjunctivitis is a viral eye infection caused by a number of different adenoviruses. The highly contagious disease causes inflammation of the cornea and conjunctiva, leading to irritation, itching, discharge and pain in the eye, swelling of the eyelids, photophobia, and blurred vision. These vision problems can last for months or even years in infected individuals. Adenovir Pharma AB aims to improve treatment of EKC with a “molecular wipe” that captures the virus and prevents it from binding to the surface of the eye.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel